NCT06470373View on ClinicalTrials.gov

A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

434

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
DRUG

RBS-001 Solution for intravitreal injection

Administer 2 mg/eye (50 uL/eye) per dose of the IP via IVT to the subjects' study eye

DRUG

Eylea® Solution for intravitreal injection

Administer 2 mg/eye (50 uL/eye) per dose of the IP via IVT to the subjects' study eye

Trial Locations (7)

16507

Erie Retina Research, Erie

38138

Charles Retina Institute, Germantown

72764

Retina Partners of Northwest Arkansas, PLLC, Springdale

76087

Strategic Clinical Research Group, LLC, Willow Park

79606

Retina Research Institute of Texas, Abilene

85021

Associated Retina Consultants - Phoenix, Phoenix

85297

Associated Retina Consultants - Gilbert, Phoenix

All Listed Sponsors
lead

Rophibio, Inc.

INDUSTRY

NCT06470373 - A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration | Biotech Hunter | Biotech Hunter